Beijing Yinmei Future Biomedical Technology

Beijing Yinmei Future Biomedical Technology is a biotechnology company specializing in the research and development of mRNA-based vaccines and therapeutics. Founded in 2021 and based in Beijing's Daxing District, the company utilizes a proprietary mRNA platform and lipid nanoparticle (LNP) delivery technology. Their pipeline primarily targets infectious diseases, including COVID-19 and influenza, as well as applications in oncology through personalized cancer vaccines. Yinmei Future has secured significant investment from leading firms such as Sequoia China Seed Fund and GL Ventures to support its R&D and manufacturing infrastructure. The company aims to provide innovative and accessible mRNA solutions for global health challenges through independent innovation and integrated manufacturing capabilities.